Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.

ABSTRACT:

Background

Mineralocorticoid receptor (MR) antagonists are the recommended medical therapy for primary aldosteronism. Whether this recommendation effectively reduces cardiometabolic risk is not well understood. We aimed to investigate the risk of incident cardiovascular events in patients with primary aldosteronism treated with MR antagonists compared with patients with essential hypertension.

Methods

We did a cohort study using patients from a research registry from Brigham and Women's Hospital, Massachusetts General Hospital, and their affiliated partner hospitals. We identified patients with primary aldosteronism using International Classification of Disease, 9th and 10th Revision codes, who were assessed between the years 1991-2016 and were at least 18 years of age. We e

SUBMITTER: Hundemer GL 

PROVIDER: S-EPMC5953512 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature